Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J

BJU international1 Jun 2002Cited by 144 (Europe PMC)

PMID12010228DOI10.1046/j.1464-410x.2002.02791.xPepBankPUB-12010228

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with nocturia, desmopressin reduced mean nocturnal voids from 3.0 to 1.7 (43%) versus 3.2 to 2.7 (12%) with placebo (P<0.001).
In plain wordsIn men with nocturia, mean nocturnal voids fell by 43% with desmopressin versus 12% with placebo.
Peptide
Desmopressin
Outcome
DecreaseMean nocturnal voids
Study
n = 151
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Nocturnal voids
3 voids
desmopressin baseline
Nocturnal voids
1.7 voids
desmopressin after treatment
Nocturnal voids
3.2 voids
placebo baseline
Nocturnal voids
2.7 voids
placebo after treatment
Reduction
43%
desmopressin
Reduction
12%
placebo
Source sentences
Summary
the mean number of nocturnal voids decreased from 3.0 to 1.7 and from 3.2 to 2.7, respectively, reflecting a mean decrease of 43% and 12% (P<0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022802
02HumanRandomized controlled trialEfficacy outcome
In men with nocturia, first sleep duration increased 59% (2.7 to 4.5 h) with desmopressin versus 21% (2.5 to 2.9 h) with placebo (P<0.001).
In plain wordsIn men with nocturia, first sleep duration increased 59% with desmopressin versus 21% with placebo.
Peptide
Desmopressin
Outcome
IncreaseFirst sleep period duration
Study
n = 151
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Increase
59%
desmopressin
Duration
2.7 h
desmopressin baseline
Duration
4.5 h
desmopressin after treatment
Increase
21%
placebo
Duration
2.5 h
placebo baseline
Duration
2.9 h
placebo after treatment
Source sentences
Summary
The mean duration of the first sleep period increased by 59% (from 2.7 to 4.5 h) in the desmopressin group, compared with an increase of 21% (from 2.5 to 2.9 h) in the placebo group (P<0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022803
03HumanRandomized controlled trialEfficacy outcome
In men with nocturia, diuresis decreased 36% (1.5 to 0.9 mL/min) with desmopressin versus 6% (1.7 to 1.5 mL/min) with placebo (P<0.001).
In plain wordsIn men with nocturia, nocturnal urine production decreased 36% with desmopressin versus 6% with placebo.
Peptide
Desmopressin
Outcome
DecreaseNocturnal diuresis
Study
n = 151
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Reduction
36%
desmopressin
Diuresis
1.5 mL/min
desmopressin baseline
Diuresis
0.9 mL/min
desmopressin after treatment
Reduction
6%
placebo
Diuresis
1.7 mL/min
placebo baseline
Diuresis
1.5 mL/min
placebo after treatment
Source sentences
Summary
The mean nocturnal diuresis decreased by 36% (from 1.5 to 0.9 mL/min) in the desmopressin group and by 6% (from 1.7 to 1.5 mL/min) in the placebo group (P<0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022804
04HumanRandomized controlled trialEfficacy outcome
In men with nocturia, the night/24-h urine-volume ratio decreased 23% with desmopressin versus 1% with placebo (P<0.001).
In plain wordsIn men with nocturia, the night/24-h urine-volume ratio decreased 23% with desmopressin versus 1% with placebo.
Peptide
Desmopressin
Outcome
DecreaseNight to 24-hour urine-volume ratio
Study
n = 151
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Ratio reduction
23%
desmopressin
Ratio reduction
1%
placebo
Source sentences
Summary
The mean ratio of night/24-h urine volume decreased by 23% and 1% (P<0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P<0.001) for the desmopressin and placebo groups, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022805
05HumanRandomized controlled trialEfficacy outcome
In men with nocturia, the night/day urine-volume ratio decreased 27% with desmopressin but increased 3% with placebo (P<0.001).
In plain wordsIn men with nocturia, the night/day urine-volume ratio decreased 27% with desmopressin but increased 3% with placebo.
Peptide
Desmopressin
Outcome
DecreaseNight to daytime urine-volume ratio
Study
n = 151
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Ratio reduction
27%
desmopressin
Ratio increase
3%
placebo
Source sentences
Summary
The mean ratio of night/24-h urine volume decreased by 23% and 1% (P<0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P<0.001) for the desmopressin and placebo groups, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022806
06HumanRandomized controlled trialSafety outcome
In men with nocturia, adverse events affected similar numbers: 15 (17%) with desmopressin and 16 (25%) with placebo.
In plain wordsIn men with nocturia, adverse events affected similar numbers: 17% with desmopressin and 25% with placebo.
Peptide
Desmopressin
Outcome
Direction not reportedAdverse events
Study
n = 151
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Adverse events
15 patients
desmopressin
Adverse events
17%
desmopressin
Adverse events
16 patients
placebo
Adverse events
25%
placebo
Source sentences
Summary
In the double-blind treatment period, similar numbers of patients had adverse events; 15 (17%) patients in the desmopressin and 16 (25%) patients in the placebo group.
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022807
07HumanRandomized controlled trialEfficacy outcome
In men with nocturia, 28 (34%) desmopressin patients versus two (3%) placebo patients had fewer than half their baseline nocturnal voids (P<0.001).
In plain wordsIn men with nocturia, 34% with desmopressin versus 3% with placebo had fewer than half their baseline nocturnal voids.
Peptide
Desmopressin
Outcome
IncreaseMore than 50% reduction in nocturnal voids
Study
n: not reported in source
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Responders
28 patients
desmopressin
Response rate
34%
desmopressin
Responders
2 patients
placebo
Response rate
3%
placebo
Source sentences
Summary
In the desmopressin group 28 (34%) patients and in the placebo group two (3%) patients (P<0.001) had fewer than half the number of nocturnal voids relative to baseline;
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022801
08HumanNon-randomized trialSafety outcome
During desmopressin dose titration in men with nocturia, serum sodium was <130 mmol/L in 10 (4%) patients.
In plain wordsDuring desmopressin dose titration in men with nocturia, blood sodium was below 130 mmol/L in 10 (4%) patients.
Peptide
Desmopressin
Outcome
Not applicableSerum sodium below 130 mmol/L
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.1, 0.2 or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Serum sodium
< 130 mmol/L
dose titration
Affected patients
10 patients
dose titration
Affected patients
4%
dose titration
Source sentences
Summary
Serum sodium levels were <130 mmol/L in 10 (4%) patients and this occurred during dose-titration.
4 context sentences(design, population, supporting numbers)
Summary · context
Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited.
Summary · context
A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg).
Summary · context
After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks.
Summary · context
In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo).
Report a problemFND-1201022808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.